Custom
Request 

Research Report Details

Author / Researcher : Global Markets Direct

Report Statistics

Number Of Pages/Tabs : 56

Number Of Charts : N/A

Published Date : 05/11/2016

Industries : Pharmaceuticals

Countries : All

Quality Score : 5

Have a question about this report?
24/7 Research Support
Talk to Zursh Analyst
+1 858 522 9998 or Email Us

Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - Pipeline Review, H1 2016
Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - Pipeline Review, H1 2016’, provides in depth analysis on Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) targeted pipeline therapeutics.

The report provides comprehensive information on the Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Additionally, the report provides an overview of key players involved in Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications.

The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - The report reviews Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) targeted therapeutics and enlists all their major and minor projects - The report assesses Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) targeted therapeutics Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

;

Companies Covered

Chrysalis Pharma SAS Griffin Discoveries BV Johnson & Johnson OSE Pharma SA Palau Pharma, S.A. Sensorion S.A. Ziarco Pharma Ltd
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) Overview 7
Therapeutics Development 8
Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - Products under Development by Stage of Development 8
Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - Products under Development by Therapy Area 9
Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - Products under Development by Indication 10
Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - Products under Development by Companies 13
Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - Therapeutics Assessment 15
Assessment by Monotherapy/Combination Products 15
Assessment by Mechanism of Action 16
Assessment by Route of Administration 18
Assessment by Molecule Type 20
Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - Companies Involved in Therapeutics Development 21
Chrysalis Pharma SAS 21
Griffin Discoveries BV 22
Johnson & Johnson 23
OSE Pharma SA 24
Palau Pharma, S.A. 25
Sensorion S.A. 26
Ziarco Pharma Ltd 27
Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - Drug Profiles 28
GD-134 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
GD-136 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
GD-48 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
JNJ-28307474 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
JNJ-28610244 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
JNJ-40279486 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
SENS-218 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Small Molecules to Agonize Histamine H4 Receptor for Cystic Fibrosis and Idiopathic Pulmonary Fibrosis - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Small Molecules to Antagonize Histamine H1 and H4 Receptor for Ophthalmology and Asthma - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Small Molecules to Antagonize Histamine H4 Receptor for Vestibular Disorders - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
toreforant tartrate - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
tritoqualine - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
UR-63325 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
ZPL-3893787 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - Dormant Projects 45
Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - Discontinued Products 48
Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - Featured News & Press Releases 49
Feb 22, 2016: Sensorion Presents SENS-218 Data at Association for Research in Otolaryngology Meeting 49
Feb 02, 2016: Phase 2a Psoriasis Study Initiated with Ziarco Lead Compound ZPL-389 50
Jan 06, 2016: Sensorion Receives Approval from the UK Drug Agency to Initiate Clinical Trial of SENS-218 50
Jun 10, 2015: Ziarco Initiates Phase 2a Clinical Trial of ZPL-389 in Atopic Dermatitis 51
Apr 23, 2015: Sensorion successfully completes the first part of the clinical trial on SENS-111, which aims to treat severe bouts of vertigo 52
Jun 18, 2014: Ziarco Secures £1.7M Grant from UK’s Technology Strategy Board to Support Phase 2a of ZPL-389 in Atopic Dermatitis 53
Jun 08, 2010: Palau Pharma Reports Positive First-In-Man Phase I Clinical Trial Results For Its Histamine H4 Receptor Antagonist UR-63325 53
Appendix 55
Methodology 55
Coverage 55
Secondary Research 55
Primary Research 55
Expert Panel Validation 55
Contact Us 55
Disclaimer 56

List of Tables
Number of Products under Development for, H1 2016 8
Number of Products under Development by Therapy Area, H1 2016 9
Number of Products under Development by Indication, H1 2016 10
Comparative Analysis by Late Stage Development, H1 2016 11
Comparative Analysis by Early Stage Products, H1 2016 12
Number of Products under Development by Companies, H1 2016 13
Products under Development by Companies, H1 2016 14
Assessment by Monotherapy/Combination Products, H1 2016 15
Number of Products by Stage and Mechanism of Action, H1 2016 17
Number of Products by Stage and Route of Administration, H1 2016 19
Number of Products by Stage and Molecule Type, H1 2016 20
Pipeline by Chrysalis Pharma SAS, H1 2016 21
Pipeline by Griffin Discoveries BV, H1 2016 22
Pipeline by Johnson & Johnson, H1 2016 23
Pipeline by OSE Pharma SA, H1 2016 24
Pipeline by Palau Pharma, S.A., H1 2016 25
Pipeline by Sensorion S.A., H1 2016 26
Pipeline by Ziarco Pharma Ltd, H1 2016 27
Dormant Projects, H1 2016 45
Dormant Projects (Contd..1), H1 2016 46
Dormant Projects (Contd..2), H1 2016 47
Discontinued Products, H1 2016 48

List of Figures
Number of Products under Development for, H1 2016 8
Number of Products under Development by Therapy Area, H1 2016 9
Number of Products under Development by Top 10 Indication, H1 2016 10
Comparative Analysis by Early Stage Products, H1 2016 12
Assessment by Monotherapy/Combination Products, H1 2016 15
Number of Products by Mechanism of Actions, H1 2016 16
Number of Products by Stage and Mechanism of Actions, H1 2016 16
Number of Products by Routes of Administration, H1 2016 18
Number of Products by Stage and Routes of Administration, H1 2016 18
Number of Products by Stage and Molecule Type, H1 2016 20

Summary of Source & Methodology

True

Global Markets Direct follows the highest standards when conducting primary and secondary research, including thousands of interviews with senior executives every year, to enable clients to make sound business decisions for their company in complete confidence. 1. 1 million-strong stakeholder group, plus 25,000 interviews annually 2. Rigorous checks on over 25,000 public and proprietary sources 3. Data modeled and forecasted with gold-standard methodology 4. Updated in real time 5. Expert insights and critical analysis from 700 experienced researchers and analysts If you would like to request the complete research methodology of this report or any additional information, please send us an email to reports@zursh.com

Download additional documents & original sources used by researcher/publisher to support the report data

Download Documents
No documents available for download

Zursh quality control analysts have developed a nice rating algorithm to independently and objectively evaluate the quality of this report.

Quality Score : 5
Content 5
Reputation 5
Sources 5
Presentation 5
Global Markets Direct is a leading provider of global business intelligence and market analysis. The company publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. With a large dedicated research and analysis capability, Global Markets Direct employs rigorous primary and secondary research techniques in developing unique data sets and research materials. At the heart of Global Markets Direct are unique databases, updated live, covering millions of rows of key information for the studied industry at a global level.